Arkolith/Insider Trading/XERS/Form 4

Shannon John Patrick Jr

See Remarks, DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Nov 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$173K
Net Open-Market Flow
-$173K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 14, 2025Option exercise(M)87K$1.55$135K2.7M
Nov 13, 2025Option exercise(M)9K$1.55$14K2.7M
Nov 13, 2025Sell(S)23K$7.46$173K2.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 14, 2025Option exercise(M)87K—$064K
Nov 13, 2025Option exercise(M)9K—$0151K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001553595-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML